News
9d
Stocktwits on MSNRegeneron Stock Drops On Mixed Results For Smoker’s Lung TreatmentRegeneron Pharmaceuticals (REGN) shares dropped nearly 10% in premarket trading Friday after mixed results from late-stage ...
6d
Clinical Trials Arena on MSNSanofi and Regeneron report results from two Phase III trials of COPD treatmentSanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...
Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...
Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results